aibioBluejay reports Q2 2026 results and $9.6 million in cash
Tickers BJDX
The company says its June 2026 private placement brought in about $7.6 million in net proceeds and that its cash should fund operations through the second quarter of 2027.
Key facts
- Company
- Bluejay Diagnostics, Inc. (NASDAQ: BJDX)
- News type
- Financings
- Primary source
- Bluejay Diagnostics, Inc. 8-K (2026-08-13)
On August 13, 2026, Bluejay Diagnostics, Inc. (NASDAQ: BJDX) reported results for the quarter ended June 30, 2026. The company ended the quarter with approximately $9.6 million in cash and cash equivalents, compared with approximately $5.2 million at December 31, 2025. During the first six months of 2026 it generated approximately $7.7 million of net cash from financing activities, including approximately $7.6 million of net proceeds from its June 2026 private placement.
The private placement
The release describes the financing only by its net proceeds and timing. It does not give the size of the placement in shares or the price per share. The sources for this story name no underwriter or placement agent for the June 2026 private placement, and the release names no bank or financial advisor for it.
Dey said: "Importantly, we believe our recent financing provides us with additional resources to execute these near-term priorities." He added that the company's cash resources are estimated to fund operations through the second quarter of 2027, and that its objective is to concentrate resources on activities that can advance Symphony toward regulatory clearance and commercial readiness.
Clinical and manufacturing progress
Bluejay completed targeted enrollment of 750 hospital patients in its SYMON-II pivotal clinical validation study. The company says it is moving toward analytical and clinical validation activities intended to support a future FDA 510(k) submission. It also signed a U.S. manufacturing contract to mitigate supply-chain risk.
Dey said the company's focus is shifting toward manufacturing readiness and the activities needed to support its planned regulatory submission and commercialization. The release describes the Symphony rapid diagnostic platform as an investigational device that is limited by United States law to investigational use.
Financial position
The release does not include a full income statement. Bluejay's XBRL financial data, drawn from its annual report filed March 6, 2026, shows research and development expense of $3.0 million for the fiscal year ended December 31, 2025, compared with $3.5 million for 2024. For 2025 the company reported net income (loss) of negative $6.8 million, compared with negative $7.7 million for 2024. Cash from operations was negative $6.1 million for 2025, compared with negative $7.8 million for 2024.
The company
Bluejay describes itself as a medical diagnostics company focused on improving patient outcomes in critical care settings through its Symphony System, a near-patient testing system for sepsis triage and monitoring of disease progression. Its first product candidate, an IL-6 Test for sepsis, is designed to provide results in approximately 20 minutes. The company says it does not yet have regulatory clearance for the Symphony System, and that it will need FDA authorization before Symphony can be marketed as a diagnostic product in the United States.
The release also describes the SYMON-II study as having completed its targeted enrollment of 750 hospital patients. It is the pivotal study that the company plans to use to validate the outcomes of SYMON-I and to support a 510(k) application.
What the release leaves open
The cash runway is short. Management estimates the cash resources will fund operations only through the second quarter of 2027, and that is the company's own estimate. The $9.6 million was largely bought with new equity, since the private placement supplied approximately $7.6 million of net proceeds, and the release gives no terms, so existing holders cannot see the dilution. Cash used in operations was $6.1 million for 2025. Finishing enrollment in SYMON-II is not a result: the release reports no data from the study, and a 510(k) submission, FDA review and a commercial launch all remain ahead, probably needing more money. Bluejay said it will concentrate its resources on activities it believes can advance Symphony toward regulatory clearance and commercial readiness. The company plans to use the SYMON-II study to support a 510(k) application to the FDA. The release gives no date for that application. It also says the Symphony IL-6 Test has not been cleared or approved by the FDA and is not currently available for commercial clinical use in the United States.